Annals of Neurology

Plasma Metabolites Link Dietary Patterns to Stroke Risk.  93:500-510. 2023

Tubers Affecting the Fusiform Face Area Are Associated with Autism Diagnosis.  93:577-590. 2023

Hydroxychloroquine for Primary Progressive Multiple Sclerosis.  90:940-948. 2021

Profile of Autism Spectrum Disorder in Tuberous Sclerosis Complex: Results from a Longitudinal, Prospective, Multisite Study.  90:874-886. 2021

Longitudinal CSF Iron Pathway Proteins in Posthemorrhagic Hydrocephalus: Associations with Ventricle Size and Neurodevelopmental Outcomes.  90:217-226. 2021

Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease.  90:76-88. 2021

Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.  89:895-910. 2021

Multisite Study of Evoked Potentials in Rett Syndrome.  89:790-802. 2021

Tuber Locations Associated with Infantile Spasms Map to a Common Brain Network.  89:726-739. 2021

Correction to: “Optimizing Patient Selection for Endovascular Treatment in Acute Ischemic Stroke (SELECT): A Prospective Multicenter Cohort Study of Imaging Selection” (Annals of Neurology, (2020), 87, 3, (419-433), 10.1002/ana.25669).  88:1056-1057. 2020

Comparison of Core Features in Four Developmental Encephalopathies in the Rett Natural History Study.  88:396-406. 2020

Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis.  88:42-55. 2020

Optimizing Patient Selection for Endovascular Treatment in Acute Ischemic Stroke (SELECT): A Prospective, Multicenter Cohort Study of Imaging Selection.  87:419-433. 2020

Using global team science to identify genetic parkinson's disease worldwide.  86:153-157. 2019

Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy.  86:42-54. 2019

Gender Inequities in the Multiple Sclerosis Community: A Call for Action.  84:958-959. 2018

N-acetylcysteine targets 5 lipoxygenase-derived, toxic lipids and can synergize with prostaglandin E2 to inhibit ferroptosis and improve outcomes following hemorrhagic stroke in mice.  84:854-872. 2018

NBEA: Developmental disease gene with early generalized epilepsy phenotypes.  84:788-795. 2018

¹⁸F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study.  82:622-634. 2017

Dendritic spines provide cognitive resilience against Alzheimer's disease.  82:602-614. 2017

Incidence and impact of subclinical epileptiform activity in Alzheimer's disease.  80:858-870. 2016

Glucocerebrosidase, Parkinson disease, and the “senses and intellect”.  80:660-661. 2016

Long-term evolution of multiple sclerosis disability in the treatment era.  80:499-510. 2016

Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial.  78:248-257. 2015

Alzheimer's disease pathology is attenuated in a CD38-deficient mouse model.  78:88-103. 2015

Training for a neurology career in a rare disease: The role of cyberconsults.  77:738-740. 2015

A fatal case of JC virus meningitis presenting with hydrocephalus in a human immunodeficiency virus-seronegative patient..  76:140-147. 2014

Hyperintense cortical signal on magnetic resonance imaging reflects focal leukocortical encephalitis and seizure risk in progressive multifocal leukoencephalopathy..  75:659-669. 2014

UBQLN2 mutation causing heterogeneous X-linked dominant neurodegeneration.  75:793-798. 2014

Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis..  73:705-713. 2013

Randomized study combining interferon and glatiramer acetate in multiple sclerosis.  73:327-340. 2013

Reply to Dr Ismailov.  73:146-147. 2013

Short- and long-term sunlight radiation and stroke incidence.  73:32-37. 2013

Mouse models of frontotemporal dementia.  72:837-849. 2012

Laminin alpha 2 enables glioblastoma stem cell growth.  72:766-778. 2012

Meta-analysis of Parkinson's Disease: Identification of a novel locus, RIT2.  71:370-384. 2012

Reply.  70:666-667. 2011

Incident cognitive impairment is elevated in the stroke belt: The REGARDS Study.  70:229-236. 2011

Got milk?.  70:3-4. 2011

Disparities in stroke incidence contributing to disparities in stroke mortality.  69:619-627. 2011

Exome sequencing allows for rapid gene identification in a Charcot-Marie-Tooth family.  69:464-470. 2011

Lipids and stroke: Looking for risk in all the wrong places?.  69:597-599. 2011

Comparative analysis of therapeutic options used for myasthenia gravis.  68:797-805. 2010

Rett syndrome diagnostic criteria: Lessons from the Natural History Study.  68:951-955. 2010

Rett syndrome: Revised diagnostic criteria and nomenclature.  68:944-950. 2010

Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis.  67:749-760. 2010

Beyond diagnosis: What biomarkers are teaching us about the "bio"logy of Alzheimer disease.  67:283-285. 2010

Considerations on discontinuing natalizumab for the treatment of multiple sclerosis.  68:409-411. 2010

Outcome of Optic Neuritis in Pediatric Demyelinating Disease.  68:S86-S86. 2010

Effect of epilepsy magnetic source imaging on intracranial electrode placement.  65:716-723. 2009

Early imaging correlates of subsequent motor recovery after stroke.  65:596-602. 2009

Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta-analytic approach.  65:268-275. 2009

Reperfusion normalizes motor activation patterns in Large-Vessel disease.  65:203-208. 2009

Estimated 10-year stroke risk by region and race in the United States: Geographic and racial differences in stroke risk.  64:507-513. 2008

Functional imaging: I. Relative predictive value of intracranial electroencephalography.  64:25-34. 2008

Functional imaging: II. Prediction of epilepsy surgery outcome.  64:35-41. 2008

Care seeking after stroke symptoms.  63:466-472. 2008

DBH -1021C→T does not modify risk or age at onset in Parkinson's disease.  62:99-101. 2007

Interferon-β for multiple sclerosis: Long-term benefits?.  61:283-285. 2007

Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease.  62:137-144. 2007

Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial.  61:14-24. 2007

Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients.  61:47-54. 2007

LRRK2 protein is a component of Lewy bodies [3].  60:617-618. 2006

Localization of LRRK2 to membranous and vesicular structures in mammalian brain.  60:557-569. 2006

Platform Session 4 (36–43).  60:s139-s141. 2006

A longitudinal functional magnetic resonance imaging study of language development in children 5 to 11 years old.  59:796-807. 2006

Magnetic source imaging versus intracranial electroencephalogram in epilepsy surgery: A prospective study.  59:835-842. 2006

Simvastatin enhances learning and memory independent of amyloid load in mice.  60:729-739. 2006

A locus for generalized tonic-clonic seizure susceptibility maps to chromosome 10q25-q26.  58:449-458. 2005

Erratum: Unusual variants of Alexander's disease (Annals of Neurology (2005) 57 (327-338)).  58:172. 2005

Distal spinal and bulbar muscular atrophy caused by dynactin mutation.  57:687-694. 2005

False-positive SCA8 gene test in a patient with pathologically proven multiple system atrophy [1].  57:462-463. 2005

Glial fibrillary acidic protein mutations in infantile, juvenile, and adult forms of Alexander disease.  57:310-326. 2005

Unusual variants of Alexander's disease.  57:327-338. 2005

Hypoperfusion without stroke alters motor activation in the opposite hemisphere.  56:796-802. 2004

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.  54:93-101. 2003

Altered hippocampal muscarinic receptors in acetylcholinesterase-deficient mice.  53:788-796. 2003

Parkin mutations and susceptibility alleles in late-onset Parkinson's disease.  53:624-629. 2003

No evidence for genetic association or linkage of the cathepsin D (CTSD) exon 2 polymorphism and Alzheimer disease.  49:114-116. 2001

Quantitative neuropathological changes in presymptomatic Huntington's disease.  49:29-34. 2001

Survival in a transgenic model of FALS is independent of iNOS expression [1].  50:273. 2001

Decreased cerebrospinal fluid levels of β-phenylethylamine in patients with Rett syndrome.  47:801-803. 2000

Influence of mutation type and X chromosome inactivation on Rett syndrome phenotypes.  47:670-679. 2000

Distribution of the mRNAs encoding torsinA and torsinB in the normal adult human brain.  46:761-769. 1999

Distribution of the mRNAs encoding torsinA and torsinB in the normal adult human brain.  46:761-769. 1999

The hereditary dystonias: An emerging story with a twist.  44:4-5. 1998

Dystonia with motor delay in compound heterozygotes for GTP- cyclohydrolase I gene mutations.  44:10-16. 1998

Expression of the early onset torsion dystonia gene (DYT1) in human brain.  43:669-673. 1998

Apolipoprotein E genotypes and age at onset of Parkinson's disease [4] (multiple letters).  44:294-295. 1998

On the pathological progression of Huntington's disease [1] (multiple letters).  44:148. 1998

Surgical treatment of hypothalamic hamartoma [3].  43:273-274. 1998

Decreased cerebrospinal fluid levels of substance P in patients with Rett syndrome.  42:978-981. 1997

Modulation of the age at onset of Parkinson's disease by apolipoprotein E genotypes.  42:655-658. 1997

Accumulation of β-amyloid precursor protein in HIV encephalitis: Relationship with neuropsychological abnormalities.  42:34-40. 1997

Intrinsic epileptogenesis of hypothalamic hamartomas in gelastic epilepsy.  42:60-67. 1997

CAG repeat number governs the development rate of pathology in huntington's disease.  41:689-692. 1997

Recommendations from the national multiple sclerosis society clinical outcomes assessment task force.  42:379-382. 1997

Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease.  39:767-778. 1996

Opportunities and challenges in academic neurology: Report of the long range planning committee of the American Neurological Association.  39:693-699. 1996

Expression of Hel-N1 and Hel-N2 in small-cell lung carcinoma..  39:679-681. 1996

Clinical outcomes assessment in multiple sclerosis.  40:469-479. 1996

Clinical outcomes and documentation of partial beneficial effects of immunotherapy for multiple sclerosis.  37:5-6. 1995

Huntington's disease gene: Regional and cellular expression in brain of normal and affected individuals.  37:218-230. 1995

Increased Risk of Parkinson's Disease in Relatives of Patients.  37:685-685. 1995

Regional distribution of protease‐resistant prion protein in fatal familial insomnia.  38:21-29. 1995

Reply.  37:685-685. 1995

Autoantibodies against the Hel‐N1 RNA‐binding protein among patients with lung carcinoma: An association with type I anti–neuronal nuclear antibodies.  36:200-205. 1994

Concentric sclerosis (Baló): Morphometric and in situ hybridization study of lesions in six patients.  35:18-30. 1994

Increased risk of Parkinson's disease in parents and siblings of patients.  36:659-661. 1994

Neuronal migration disorders: Positron emission tomography correlations.  35:290-297. 1994

Predictive value of induction of psychogenic seizures by suggestion.  35:359-361. 1994

Rett syndrome: Controlled study of an oral opiate antagonist, naltrexone.  35:464-470. 1994

VISUAL PHENOMENA LIMITED TO THE HEMIANOPIC FIELD IN LESIONS OF THE CENTRAL VISUAL PATHWAYS.  34:279-279. 1993

Clinical determinants of dememtia related to stroke.  33:568-575. 1993

Correlation of myelin basic protein‐like material in cerebrospinal fluid of multiple sclerosis patients with their response to glucocorticoid treatment.  33:10-17. 1993

Retinal ganglion cells in Alzheimer's disease and aging.  33:248-257. 1993

Mitochondrial oxidative phosphorylation defects in Parkinson's disease.  32:113-114. 1992

Preferential loss of striato‐external pallidal projection neurons in presymptomatic Huntington's disease.  31:425-430. 1992

Reply.  32:227-227. 1992

Reply.  32:595-596. 1992

Cerebral amyloid angiopathy without and with cerebral hemorrhages: A comparative histological study.  30:637-649. 1991

Excitatory amino acid binding sites in the caudate nucleus and frontal cortex of huntington's disease.  30:785-793. 1991

Mitochondrial oxidative phosphorylation defects in parkinson's disease.  30:332-339. 1991

Sleep-related focal motor seizures in bilateral central macrogyria..  28:840-842. 1990

Estimation of familial risk in Alzheimer's disease.  27:338-340. 1990

Phosphorus magnetic resonance spectroscopy of patients with mitochondrial cytopathies demonstrates decreased levels of brain phosphocreatine.  27:626-630. 1990

Reply.  27:340-341. 1990

Reply.  28:840-840. 1990

Assessment of genetic risk for alzheimer's disease among first‐degree relatives.  25:485-493. 1989

Cerebrospinal fluid biogenic amines and biopterin in rett syndrome.  25:56-60. 1989

Tomaculous neuropathy presenting as acute recurrent polyneuropathy.  26:98-100. 1989

Diagnostic criteria for Rett syndrome. The Rett Syndrome Diagnostic Criteria Work Group..  23:425-428. 1988

An isoelectric focusing study in herpes simplex virus encephalitis.  24:227-232. 1988

Reply.  22:96-97. 1987

Rett's syndrome: Characterization of respiratory patterns and sleep.  21:377-382. 1987

Bilateral lucency of the globus pallidus complicating methylmalonic acidemia.  20:364-366. 1986

Facioscapulohumeral dystrophy presenting in infancy with facial diplegia and sensorineural deafness.  17:513-516. 1985

The role of plasma lipids in carotid bifurcation atherosclerosis.  17:301-303. 1985

Acquired immune deficiency syndrome and multiple tract degeneration in a homosexual man.  15:502-505. 1984

The comparative effects of organic brain disease on cerebral blood flow and measured intelligeence.  13:155-159. 1983

Electrophysiological and clinical correlation in myasthenia gravis.  12:348-354. 1982

Acute autonomic and sensory neuropathy.  8:441-444. 1980

Sarcoid polyneuropathy: A histologically proved case.  7:178-181. 1980

Mechanisms of acute carotid stroke.  6:245-252. 1979

Tarsal tunnel syndrome: Electrophysiological study.  5:327-330. 1979

Rapid improvement in nerve conduction velocity following renal transplantation.  4:369-373. 1978

The malignancy of dementias.  3:559-561. 1978

Botulism: Electrophysiological studies.  1:481-485. 1977